Our team has many decades of combined experience across multiple disciplines of the biotechnology, pharmaceutical and life sciences industry.
One of our key strengths is our extensive network across senior leadership, finance, operational disciplines of our industry, technical and clinical key opinion leaders, and all specialists needed to ensure success, domestically and globally.
We choose to focus on innovative approaches that could have truly transformative effects on patient care.
We are patient and in this for the long haul, looking to build something hand-in-hand with you.
Three core focus areas with the ultimate goal of advancing novel therapeutic and diagnostic approaches for patients that currently have no therapeutic options.
FOCUS AREA 1
Re-building companies that have promising, commercially viable technology & have been unable to progress in development for reasons unrelated to the science or technology.
FOCUS AREA 2
Building new companies based on technologies identified using Hibiscus BioVentures’ screening and diligence engine.
FOCUS AREA 3
25% of fund assets dedicated to participating in passive investments where HB does not lead, or supporting existing HB I investments and companies that have previously been identified.
Chris received his Ph.D. training in Biochemistry and Biophysics at Rice University and the University of Houston, where he was a National Institutes of Health Predoctoral Fellow. Following his Ph.D. training Chris was an NIH Postdoctoral Fellow at The Johns Hopkins University School of Medicine where he studied the structure of the Cystic Fibrosis Transmembrane Conductance Receptor (CFTR). In addition, Chris obtained his law degree from Georgetown University. Bringing years of startup experience to Orchid Chris was the founder of FirstStage Bioventures, Seguro Surgical, EncephRx and Camden Pharmaceuticals, and was the General Counsel and V.P. of Drug Discovery at Alba Therapeutics. In addition to serving as outside General Counsel to numerous biotech companies including Viela Bio and NexImmune, Chris holds adjunct faculty appointments in the School of Business and Whiting School of Engineering at Johns Hopkins University.
*Note that Dr. Jeffers is not acting as a lawyer in any capacity in his role as Managing Director of Hibiscus BioVentures. As such, no conversations with Dr. Jeffers are privileged, and Dr. Jeffers will not give legal advice through any interaction with Hibiscus BioVentures or any affiliated company.
Prior to HB and B&S, Josh has spent his career at several boutique investment banks and consultancies, including Trout Capital and the Maxim Group, and has a passion for early-stage drug development to serve patients with unmet medical needs. He is also a Venture Advisor at the Israel Biotech Fund (IBF).
Josh is on the boards of Asclepix, Inc. and NexImmune, Inc. (board observer). He is also on the Boards of several-not for-profit organizations focused on education and economic development, including Trickle Up, Family Promise, and Getting Out and Staying Out (Action Board).
Josh received a Bachelor of Arts from Rutgers College and studied Conflict Management at Drew University.
A former management consultant with McKinsey & Company in its Pharmaceutical and Medical Products practice, Michael also has a background in corporate finance and sell-side analyst research, with deep knowledge of the pharmaceutical/biotech industry. Mr. King holds an M.B.A. with Honors from the Columbia Graduate School of Business.
Outside of HB, Khatija is a serial entrepreneur; currently a CEO of BioSapien Inc. BioSapien’s key asset is a 3D printed drug delivery platform.
Khatija is also involved in non-profit work involving building water pumps in South Asia and volunteering at Habitat for Humanity in NYC to build homes globally. Her recent trip was to El Salvador to build a home with Habitat for Humanity. She has served on the Habitat for Young Professionals Board for NYC.
Outside of professional work, most of the time is spent on snow hills, rock walls and race tracks.
AsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President
AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
View All News
We are interested in hearing from you and welcome the opportunity to explore whether we can work together
2275 Research Boulevard, Suite 500,
Rockville, MD 20850